Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Easy Mark who wrote (289)	3/18/1998 3:33:00 PM
From: Manny Gugliuzza	Read Replies (1) \| Respond to of 1510

mark, the quality is there, and they must continue to prove this even after fda approval. i have no idea what their production capacity is, amounts used per individual or for what length of time or intervals the remune is given. could you please supply this information to support their production capability for that (large fraction). how much of the population with aids do they expect to be treating? this figure must be known to support production capacity also. thanks and appreciate your information in advance. ar.